SecBot SecBot
8-K ·Filed Aug 5, 2026

XNCR

Xencor Inc
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001326732-26-000055
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Alexion settlement removes a major overhang and provides $105M in cash, extending runway through 2028. Key catalysts ahead: XmAb819 ESMO oral presentation (Oct 2026) and XENITH-UC interim analysis (year-end 2026). The XmAb541 Fast Track designation adds regulatory optionality. Monitor for potential partnership interest in the TL1A franchise (XmAb942/XmAb412) given the competitive landscape.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

XNCR drug pipeline →

XmAb819

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unknown — pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
Next catalyst
None dated

What to watchWatch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$20.00
T+0 close · Aug 5, 2026 · via day close
Latest settled
+49.10%
T+60 · $29.82
Vs SPY
+50.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $20.00entry
  2. T+1 · 3mo ago +4.05%α +3.44% · $20.81
  3. T+5 · 3mo ago +14.95%α +13.74% · $22.99
  4. T+20 · 3mo ago +33.10%α +32.50% · $26.62
  5. T+60 · 18d ago +49.10%α +50.77% · $29.82
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xencor reported Q2 2026 revenue of $51.2M (vs $18.9M consensus) and EPS of -$0.29 (vs -$0.84 consensus), a significant beat driven by a $27.6M royalty catch-up from the Alexion Ultomiris settlement and a $10M Zenas milestone. The company raised its year-end cash guidance to $420M-$440M (from $380M-$400M) and extended its cash runway through 2028. Pipeline milestones remain on track with XmAb819 ESMO data and XmAb942 XENITH-UC interim analysis expected by year-end.

Key Financial Metrics

EPS
−$0.29
est −$0.84 · +65.5%
Revenue
$51.2M
est $18.9M · +171.0% · +17.5% YoY
Rating
strong beat

Key Facts

  • Revenue of $51.2M beat consensus of $18.9M by 171%
  • EPS of -$0.29 beat consensus of -$0.84 by 65.6%
  • Net loss narrowed to -$21.7M from -$30.8M YoY
  • Raised year-end 2026 cash guidance to $420M-$440M from $380M-$400M
  • Cash runway extended through 2028
  • Alexion settlement provides $105M total ($52.5M due Aug 2026, $52.5M in 2027)
  • XmAb819 ccRCC data accepted for oral presentation at ESMO Oct 2026
  • XmAb942 XENITH-UC blinded interim analysis on track for year-end 2026
  • XmAb541 granted FDA Fast Track designation for germ cell tumors
  • XmAb412 first-in-human study initiated in Q3 2026

Financial Impact

Revenue beat of $32.3M vs consensus, driven by $27.6M Alexion royalty catch-up and $10M Zenas milestone; net loss improved by $9.1M YoY; cash guidance raised by $40M

revenueepscashcash runway

Risk Factors

  • XmAb541 hearing impairment toxicity could limit commercial potential despite Fast Track designation
  • XmAb942 XENITH-UC Phase 2b data risk, TL1A space is competitive with Roche/Teva and Merck/Prometheus
  • Revenue is lumpy and dependent on partnership milestones and royalty settlements
  • Operating burn rate increasing ($71.9M R&D in Q2 vs $61.7M YoY)
  • No approved products, all value is in pipeline optionality

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326732-26-000055
Document: xncr-20260805.htm0001326732-26-000055
Document: 0001326732-26-000055-index-headers.html0001326732-26-000055
Document: 0001326732-26-000055-index.html0001326732-26-000055
Document: 0001326732-26-000055.txt0001326732-26-000055
8-K Data (Synthetic)0001326732-26-000055

Track record

20 reports on XNCR

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
  3. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
  6. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
  7. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
  8. Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
  9. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026